[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-376806-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-376806-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","novel-biomarkers-for-early-detection-of-gastric-cancer","Novel biomarkers for early detection of gastric cancer","","Gastric cancer (GC) remains a major cause of cancer-related mortality worldwide, largely because fewer than half of cases are detected at an advanced stage owing to limited early symptoms. GC shows heterogeneity driven by genetic and somatic mutations, making early detection and monitoring tumor progression essential. Current endoscopic and radiologic methods are invasive, costly, and time-consuming, motivating molecular noninvasive approaches. This review summarizes recent blood-based biomarker developments for diagnosis and postoperative minimal residual disease monitoring, including circulating DNA, RNA, extracellular vesicles, and proteins.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/novel-biomarkers-for-early-detection-of-gastric-cancer/376806/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/novel-biomarkers-for-early-detection-of-gastric-cancer/376806.png","ImageObject",300,407,{"name":42,"@type":43},"Riley","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-24",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is early detection of gastric cancer difficult with current methods?","Question",{"text":63,"@type":64},"Less than half of gastric cancer cases are diagnosed at an advanced stage because early symptoms are lacking. Conventional endoscopic screening requires high sensitivity and specificity, and the procedures can be costly and resource intensive.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What problems do semi-invasive endoscopic and radiologic approaches create?",{"text":68,"@type":64},"These approaches are described as invasive, costly, and time-consuming. They can also be limited in capturing concealed tumors due to the need for higher diagnostic performance.",{"name":70,"@type":61,"acceptedAnswer":71},"Which types of blood-based biomarkers are discussed for early detection?",{"text":72,"@type":64},"The review highlights circulating DNA and RNA, extracellular vesicles, and proteins as blood-based biomarkers that are being investigated for diagnostic use and monitoring postsurgical minimal residual disease.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},376806,1790564493,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":118,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":104},1374391975076,"https://ap-avatar.wpscdn.com/avatar/14000253ca4ec9f6853?x-image-process=image/resize,m_fixed,w_180,h_180&k=1783305029341752051","| W | J | G | World Journal of\u003Cbr>Gastroenterology |\n| --- | --- | --- | --- |\n\nSubmit a Manuscript: [https://www.f6publishing.com](https://www.f6publishing.com) World J Gastroenterol 2023 May 7; 29(17): 2515-2533  \nDOI: 10.3748/wjg.v29.i17.2515 ISSN 1007-9327 (print) ISSN 2219-2840 (online)  \nREVIEW  \nNovel biomarkers for early detection of gastric cancer  \nTasuku Matsuoka, Masakazu Yashiro  \nSpecialty type: Gastroenterology and hepatology  \nProvenance and peer review:  \nInvited article; Externally peer reviewed.  \nPeer-review model: Single blind  \nPeer-review report’s scientific quality classification  \nGrade A (Excellent): 0  \nGrade B (Very good): B, B  \nGrade C (Good): C, C  \nGrade D (Fair): 0  \nGrade E (Poor): 0  \nP-Reviewer: Chen X, China; Li DH, China; Zhang Y, China; Zhao Q, China  \nReceived: November 19, 2022  \nPeer-review started: November 19, 2022  \nFirst decision: January 2, 2023  \nRevised: January 31, 2023  \nAccepted: April 13, 2023  \nArticle in press: April 13, 2023  \nPublished online: May 7, 2023  \nTasuku Matsuoka, Masakazu Yashiro, Molecular Oncology and Therapeutics, Osaka Metropolitan University Graduate School of Medicine, Osaka 5458585, Japan  \nCorresponding author: Masakazu Yashiro, MD, PhD, Assistant Professor, Molecular Oncology and Therapeutics, Osaka Metropolitan University Graduate School of Medicine, 1-4-3 Asahimachi, Abeno-ku, Osaka 5458585, [Japan.](Japan. i21496f@omu.ac.jp)[ i21496f@omu.ac.jp](Japan. i21496f@omu.ac.jp)  \nAbstract  \nGastric cancer (GC) remains a leading cause of cancer-related death worldwide. Less than half of GC cases are diagnosed at an advanced stage due to its lack of early symptoms. GC is a heterogeneous disease associated with a number of genetic and somatic mutations. Early detection and effective monitoring of tumor progression are essential for reducing GC disease burden and mortality. The current widespread use of semi-invasive endoscopic methods and radiologic approaches has increased the number of treatable cancers: However, these approaches are invasive, costly, and time-consuming. Thus, novel molecular noninvasive tests that detect GC alterations seem to be more sensitive and specific compared to the current methods. Recent technological advances have enabled the detection of blood-based biomarkers that could be used as diagnostic indicators and for monitoring postsurgical minimal residual disease. These biomarkers include circulating DNA, RNA, extracellular vesicles, and proteins, and their clinical applications are currently being investigated. The identification of ideal diagnostic markers for GC that have high sensitivity and specificity would improve survival rates and contribute to the advancement of precision medicine. This review provides an overview of current topics regarding the novel, recently developed diagnostic markers for GC.  \nKey Words: Gastric cancer; Diagnostic biomarkers; Early detection; Liquid biopsy  \n©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.  \n WJG  [https://www.wjgnet.com](https://www.wjgnet.com) 2515 May 7, 2023  Volume 29  Issue 17   \nMatsuoka T et al. Novel biomarkers of GC  \nCore Tip: Gastric cancer (GC) is a major unsolved clinical problem. It is the fifth most diagnosed cancer in the world, and the fourth most frequent cause of cancer-related deaths worldwide. The outcome of advanced GC remains tremendously poor despite the use of surgery and adjuvant therapy. Therefore, the detection new biomarkers for early diagnosis will be potential therapeutic strategies for improving survival of GC patients. The aim of this review is to summarizes the current status and approaches for novel biomarkers, which could be useful for early diagnosis.  \nCitation: Matsuoka T, Yashiro M. Novel biomarkers for early detection of gastric cancer. World J Gastroenterol 2023; 29(17): 2515-2533  \nURL: [https://www.wjgnet.com/1007-9327/full/v29/i17/2515.htm](https://www.wjgnet.com/1007-9327/full/v29/i17/2515.htm)  \nDO","cbCaimgODdRERtIJ","https://ap.wps.com/l/cbCaimgODdRERtIJ","pdf",2326394,"English","# Abstract\n# Core Tip\n# Introduction\n## Need for early screening and diagnosis\n## Limitations of current clinical approaches\n# Key Words","[{\"question\":\"Why is early detection of gastric cancer difficult with current methods?\",\"answer\":\"Less than half of gastric cancer cases are diagnosed at an advanced stage because early symptoms are lacking. Conventional endoscopic screening requires high sensitivity and specificity, and the procedures can be costly and resource intensive.\"},{\"question\":\"What problems do semi-invasive endoscopic and radiologic approaches create?\",\"answer\":\"These approaches are described as invasive, costly, and time-consuming. They can also be limited in capturing concealed tumors due to the need for higher diagnostic performance.\"},{\"question\":\"Which types of blood-based biomarkers are discussed for early detection?\",\"answer\":\"The review highlights circulating DNA and RNA, extracellular vesicles, and proteins as blood-based biomarkers that are being investigated for diagnostic use and monitoring postsurgical minimal residual disease.\"}]","Novel biomarkers for early detection of gastric cancer | PDF",1790221372]